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Abstract
Gliomas are the most common primary brain tumors. Among them,
glioblastoma (GBM) possesses the most malignant phenotype. Despite the current
standard therapy using an alkylating anticancer agent, temozolomide, most patients
with GBM die within 2 years. Novel chemotherapeutic agents are urgently needed
to improve the prognosis of GBM. One of the solutions, drug repositioning, which
broadens the indications of existing drugs, has gained attention. Herein, we catego-
rize candidate agents, which are newly identified as therapeutic drugs for malignant
glioma into 10 classifications based on these original identifications. Some drugs are
in clinical trials with hope. Additionally, the obstacles, which should be overcome in
order to accomplish drug repositioning as an application for GBM and the future
perspectives, have been discussed.
Keywords: glioma, glioblastoma, drug repositioning, chemotherapy,
temozolomide, existing drugs, pre-drugs
1. Introduction
Many diseases require the development of new drugs for effective treatment.
The relevance of drug repurposing in medical science has progressively grown
recently. The increasing interest in drug repurposing is realized based on the
increase of related academic publications.
Annually, approximately 23 per 100,000 people suffer from tumors of the
central nervous system (CNS). Gliomas, which account for 25% of all CNS tumors,
are the most common primary brain tumors, and most are malignant [1]. Glioblas-
toma (GBM) is a malignant glioma with the worst prognosis, as it accounts for 60%
of all gliomas and is classified as grade IV by the World Health Organization
(WHO) [1, 2]. Despite aggressive therapies, the median overall survival (OS) of
patients who suffer from GBM is only 15–18 months [1, 3].
The current treatments for GBM are maximum surgical resection and adjuvant
chemoradiotherapy. The first-line agent for chemotherapy is temozolomide (TMZ),
an imidazotetrazinone derivative [4]. TMZ acts as a major groove-directed
deoxyribonucleic acid (DNA)-alkylating agent, and its molecular weight is only
194 Da [4]. A phase III clinical trial revealed that concomitant and adjuvant TMZ
with radiotherapy is effective for the treatment of patients with primary GBM [5].
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Approximately half of the cases of GBM have a methylation of the
O6-methylguanine-DNA methyltransferase (MGMT) promoter, and these cases are
associated with a favorable outcome after concomitant and adjuvant TMZ with
radiotherapy [6]. MGMT potentially removes methyl adducts at the O6 position
of guanine and indicates resistance to alkylating agents; however, the methylation
of the MGMT promoter interferes with MGMT activity and induces glioma
cell death [6].
Clinical trials have revealed the therapeutic benefit of bevacizumab (BEV), a
recombinant, humanized, monoclonal antibody against vascular endothelial growth
factor (VEGF), in patients with cancer [7]. Large-scale clinical studies have been
performed to investigate the therapeutic effects of BEV in patients with newly
diagnosed GBM [8, 9]. However, the clinical benefits of BEV in patients with glioma
are still unknown.
Research into drug repositioning for GBM is now expanding, although no
effective drug has yet been reported with strong and solid evidence. Herein, we
focus on candidate agents with therapeutic effects in malignant glioma and that
have undergone clinical trials to evaluate their efficacy in patients. We also describe
the issues of drug repositioning in malignant glioma.
2. Current candidate agents for glioma
Here, we categorize candidate agents into 10 classifications (Table 1).
2.1 Antidiabetic drugs
2.1.1 Metformin
The intracellular metabolic pathway of cancer cells differs from that of normal
cells, as represented by the Warburg effect, and is considered as a cancer therapeu-
tic target. Metformin is a biguanide antidiabetic drug that exerts a hypoglycemic
effect via the suppression of gluconeogenesis in the liver and promotion of glucose
uptake in the muscle and adipose tissues. The antitumor effects of metformin are
widely known and reported in various cancers, such as breast cancer [10].
Basic research with metformin in glioma cells and glioma stem-like cells (GSCs)
has shown that metformin targets multiple pathways (Figure 1). Metformin
activates AMP-activated protein kinase (AMPK) via the inhibition of oxidative
phosphorylation in mitochondrial complex I, which increases the AMP/ATP ratio,
thereby inhibiting the mammalian target of rapamycin (mTOR) and promoting
apoptosis [11, 12]. The metformin-mediated activation of AMPK, followed by the
activation of forkhead box O3 (FOXO3), induces GSC differentiation and reduces
tumorigenicity [13]. The Cancer Genome Atlas has reported missense mutations in
isocitrate dehydrogenase (IDH) genes 1 and 2. D-2-Hydroxyglutarate (D-2HG), a
cancer metabolite produced by the mutant IDH protein, contributes to the devel-
opment and progression of cancer. The conversion of glutamine to α-ketoglutarate
(αKG) is catalyzed by glutamate dehydrogenase (GDH), and the inhibition of GDH
by metformin reduces the production of D-2HG in glioma with the IDH 1/2 muta-
tion [14]. Chloride intracellular channel 1 (CLIC1) is involved in the progression of
various cancers, including GBM [15–17]. CLIC1 is involved in the regulation of the
G1/S transition, and metformin causes G1 cell cycle arrest in GSCs by the selective
inhibition of CLIC1 [18].
An epidemiological study using the Clinical Practice Research Datalink reported
that the use of metformin is not associated with a reduced risk of glioma [19]. In a
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Candidate agent Original indication disease Mechanism of original disease Mechanism of anti-glioma effect CT Refs.
2.1 Antidiabetic drugs 2.1.1 Metformin Diabetes mellitus Suppress gluconeogenesis in the liver Activate AMPK
Inhibit glutamate dehydrogenase
NY [10–20]
2.2 Antihypertensive
drugs
2.2.1 Angiotensin II
receptor blocker
Hypertension Block angiotensin II receptor Inhibit vascular endothelial growth factor III [21–25]
2.2.2 β-blocker Hypertension Block β receptor Decrease cAMP levels NY [26, 27]
2.2.3 Calcium
channel blocker
Hypertension Block calcium channel Inhibit hippo pathway NY [28, 29]
2.3 Antiepileptic
drugs
2.3.1 Valproic acid Epilepsy Block sodium channel Inhibit GSK3β NY [31–39]
2.3.2 Levetiracetam Epilepsy Block calcium channel Inhibit MGMT expression II [40, 41]
2.4 Pesticides 2.4.1 Chloroquine Malaria (Plasmodium spp.) Inhibit heme polymerization Inhibit TGF-β and NF-κB II [42–46]
2.4.2 Pentamidine Pneumocystis pneumonia Inhibition of glucose metabolism, protein synthesis, amino
acid transport and ribonucleic acid synthesis
Unknown NY [47–49]
2.5 Antipsychotic
drugs
2.5.1 Fluvoxamine Depression Selective serotonin reuptake inhibitor Suppress the activity of actin polymerization
regulators
NY [50–57]
2.5.2 Fluspirilene Schizophrenia Dephenylbutylpiperidine Inhibit activation of STAT3 NY [58–62]
2.6 Antineoplastic
drugs
2.6.1 Eribulin Breast cancer Inhibit of microtubule activity Inhibitor of telomerase reverse transcriptase- RNA-
dependent
II [63–76]
2.7 Anti-inflammatory
drugs
2.7.1 Acetylsalicylic
acid drugs
Fever, inflammation disease Inhibit cyclooxygenase Activate connexin 43, suppress Wnt/β-catenin/T-cell
factor signaling and SHH/GLI1 pathway
NY [77–81]
2.7.2 Sulfasalazine Rheumatoid arthritis Block activation of NF-κB Block activation of NF-κB I/II [82–86]
2.8 Multiple drug
combination therapy
2.8.1 CLOVA
cocktail
– – Inhibit GSK3β I/II [87–90]
2.8.2 CUSP9*
treatment
– – Suppress multiple molecule pathway NY [91, 92]
2.8.3 FTT cocktail – – Inhibit ROCK2/moesin/β-catenin pathway, suppress
TGF-β
NY [93–96]
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Candidate agent Original indication disease Mechanism of original disease Mechanism of anti-glioma effect CT Refs.
2.9 Other drugs 2.9.1 Disulfiram Alcoholism Inhibitor of ALDH Inhibiting polo-like kinese-1 II [97–101]
2.9.2 Statins Dyslipidemia Inhibited 3-hydroxy-3-methylglutaryl-coenzyme A
reductase
Activate transcription factor-2 and c-jun, suppress
ERK
NY [102–106]
2.10 Pre drugs 2.10.1 Kenpaullone - - Inhibit GSK3β NY [107–111]
2.10.2 2-
Fluoropalmitic acid
- - Dephosphorylate ERK, suppress MMP-2 NY [112–115]
ALDH, aldehyde dehydrogenase; AMPK, AMP-activated protein kinase; CT, clinical trial; ERK, extracellular signal-regulated kinase; GLI1, glioma-associated oncogene homolog 1; GSK3β, glycogen synthase kinase 3β; MGMT,
O6-methylguanine-DNA methyltransferase; MMP-2, matrix metalloproteinase-2; NF-κB, nuclear factor- kappaB; NY, not yet; ROCK2, Rho-associated protein kinase 2; SHH, sonic hedgehog; STAT3, signal transducer and activator of
transcription 3; TGF-β, tumor growth factor-β.
Table 1.
The list of candidate agents.
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pooled analysis that included 1731 patients from large-scale randomized controlled
trials, the use of metformin was not significantly associated with OS or progression-
free survival (PFS) in patients with newly diagnosed GBM [20]. Although the
results of existing retrospective and epidemiological studies are somewhat discour-
aging, randomized clinical trials are underway, and we expect to see encouraging
results in the future.
2.2 Antihypertensive drugs
2.2.1 Angiotensin II (AT2) receptor blocker
AT2 plays a major role in the renin-angiotensin-aldosterone system and regu-
lates vascular homeostasis, mainly via the activation of angiotensin I receptor
(AT1R) and AT2 receptor. Recent studies have revealed that AT2 has roles in cell
proliferation, differentiation, apoptosis, and migration. Furthermore, AT2 induces
angiogenesis via the stimulation of growth factors such as VEGF, which suggests
that AT2 is a target for cancer therapy [21, 22]. Rivera et al. first reported the
presence of AT1R in glioma cells and demonstrated that the selective blockade of
AT1R with losartan in C6 glioma rats exerts antitumor effects via the inhibition of
tumor growth and angiogenesis [22]. The group also showed that treatment with
losartan inhibits tumor growth via the inhibition of VEGF and promotes apoptosis
in vitro and in vivo [23]. A retrospective analysis of 81 patients with newly diag-
nosed GBM showed that the administration of an AT2R blocker or angiotensin-
converting enzyme (ACE) inhibitor with the current treatment is associated with
reduced brain edema and steroid requirements and improved clinical outcomes
[24]. Nevertheless, the ASTER trial (NCT01805453), a randomized, placebo-
controlled trial, which included losartan to the current treatment for patients with
Figure 1.
Antitumor mechanisms of metformin in glioma. The inhibition of oxidative phosphorylation in mitochondrial
complex I induces the inhibition of mammalian target of rapamycin complex 1 (mTORC1) and activation of
FOXO3 via activating AMPK. The inhibition of GDH reduces the D-2HG production via αKG reduction in
IDH 1/2 mutation glioma. Selective inhibition of CLIC1 causes G1 cell cycle arrest in GSCs.
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GBM, did not show any difference in steroid requirements or a significant increase
in the median OS [25].
2.2.2 β-Blocker
Tewarie et al. summarized previous preclinical and clinical studies about the
effects of β-blockers on gliomas and noted reduced cell proliferation via a decrease
in cAMP levels, time-dependent cell cycle arrest, and reduced cell migration [26].
However, in a retrospective cohort study of 218 patients with recurrent GBM,
Johansen et al. observed no correlation between the usage of β-blockers and OS and
PFS [27].
2.2.3 Calcium channel blocker
The altered expression and activity of specific Ca2+ channels and pumps have
been reported in malignant gliomas [28]. Amlodipine, a commonly used antihyper-
tensive drug, was shown to inhibit tumor growth by the inhibition of YAP/TAZ
signaling via the hippo pathway, which is involved in tumor malignancy by the
activation of store-operated Ca2+ entry. This allows intracellular Ca2+ influx [29].
Most research on calcium signaling in GBM is recent and further study is warranted.
2.3 Antiepileptic drugs
A common symptom of GBM is epilepsy, which occurs in half of all cases; thus,
patients are often treated with antiepileptic drugs, such as valproic acid (VPA) and
levetiracetam (LEV) (Figure 2). Enzymatic modifications of histone proteins that
regulate gene expression have been investigated as therapeutic drug targets. His-
tones are modified by histone acetyltransferase (HAT) and histone deacetylase
(HDAC). A HDAC inhibitor (HDACi) enhances the acetylation by HAT and causes
a hyperacetylated state, which exerts multiple antitumor effects such as cell differ-
entiation, apoptosis, cell cycle arrest, sensitivity to chemotherapy, and inhibition of
migration and angiogenesis [30].
2.3.1 Valproic acid
Recently, VPA has been shown to be an effective HDACi and has been proposed
as a drug for cancer treatment [31]. VPA inhibits the proliferation of glioma cells
and enhances radiosensitivity by increasing hyperacetylation in vitro and in vivo
[32]. Another antitumor effect of VPA is the induction of apoptosis by the inhibi-
tion of GSK3β via the activation of Akt/ERK [33]. According to several studies, the
inhibition of GSK3β suppresses survival and proliferation and induces apoptosis in
human GBM cells [34]. However, some meta-analyses have revealed that the clini-
cal benefit of VPA combination treatment in patients with GBM was
contraindicated [35–39], and further studies are warranted.
2.3.2 Levetiracetam
LEV has been shown to increase HDAC1 transcription, recruit the mSin3A/
HDAC1 corepressor complex on the MGMT promoter, and inhibit MGMT expres-
sion through the direct binding of p53 to the MGMT promoter [40]. Thus, LEV
inhibits glioma cell proliferation and significantly potentiates the cytotoxic effects
of TMZ in glioma cells and GSCs [40, 41]. A phase II clinical trial (NCT02815410) is
ongoing and the results are expected in the future.
6
Drug Repurposing
2.4 Pesticides
2.4.1 Chloroquine (CHQ)
CHQ is a therapeutic drug for the treatment of malaria [42]. This agent has
antitumor effects for some cancer cells, including glioma cells [43]. However, the
mechanism of the antitumor effect of CHQ in glioma is not well known. Some
studies have suggested that CHQ leads to cancer cell death by controlling autophagy
[44], and recent research has revealed more effects of CHQ treatment. CHQ adjusts
the metabolism of amino acids and inhibits glycogenesis [42]. CHQ administration
also induces the alteration of mitochondrial membrane potential in glioma cells and
causes apoptosis [45]. Some studies have investigated the molecular signaling asso-
ciated with CHQ treatment. The molecular signaling changes in glioma cells caused
by CHQ include the inhibition of the signaling pathway of transforming growth
factor-β (TGF-β) and nuclear factor-kappaB (NF-κB), which play a role in tumori-
genesis [42, 45]. CHQ treatment also suppresses glioma cell invasion by the inhibi-
tion of matrix metalloproteinase-2 (MMP-2) and improved radiosensitivity by the
accumulation of glioma cells in the G2/M phase [45]. Based on the results of these
in vitro studies, clinical trials that investigated the therapeutic effects of CHQ in
patients with glioma have been conducted [43]. In a randomized trial (double-
blind, placebo-controlled) of patients with primary GBM, there were no statistically
significant differences between the CHQ treatment group and the placebo group;
however, the death rate in the CHQ group was half as large as that in the placebo
group [46]. Further clinical trials are in progress (NCT03243461, NCT02432417,
and NCT02378532).
Figure 2.
Antitumor mechanisms of VPA and LEV in glioma. VPA: hyperacetylation of histones via the inhibition of
HDAC suppresses cell proliferation and increases radiosensitivity. The activation of Akt/extracellular
signal-regulated kinase (ERK) inhibits glycogen synthase kinase-3β (GSK3β) and induces apoptosis. LEV:
recruitment of the mSin3A/HDAC1 corepressor complex and direct binding to the MGMT promoter via p53.
Abbreviations: HAT, histone acetyltransferase; MEK, mitogen-activated protein kinase/ERK kinase; PI3K,
phosphoinositide 3-kinase; TMZ, temozolomide.
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2.4.2 Pentamidine
Pentamidine is effective in the treatment of pneumonia caused by Pneumocystis
jirovecii. This drug exerts its therapeutic effects via the inhibition of glucose metab-
olism, protein synthesis, amino acid transport, and ribonucleic acid (RNA) synthe-
sis [47]. Previous studies have shown the therapeutic effects of pentamidine in
various cancers [48]. One in vitro study revealed that pentamidine suppressed
cancer activity via the inhibition of phosphatase of regenerating liver (PRL) [48]
and the inhibition of PRL phosphatase suppressed the activation of Akt and ERK
[49]. Based on these studies, we investigated the effect of pentamidine in glioma
cells and GSCs. Pentamidine suppressed the proliferation of glioma cells and GSCs
and reduced the stemness of GSCs. Additionally, there are clinical benefits to
repurposing pentamidine as the therapeutic drug for malignant glioma, because the
current chemoradiotherapy sometimes induces lymphopenia as a side effect and
patients might suffer from pneumonia caused by P. jirovecii. Further research to
investigate the molecular mechanism of pentamidine is in underway. In the future,
clinical trials are warranted to determine the benefit of pentamidine for patients
with malignant glioma.
2.5 Antipsychotic drugs
2.5.1 Fluvoxamine
Fluvoxamine has been used as an antidepressant since 1986 and is widely applied
in the treatment of anxiety disorders owing to its selective serotonin reuptake inhib-
itor activity, which helps maintain sufficient serotonin levels in the brain to function
[50, 51]. Recently, a new screeningmethod for the quantitative determination of actin
polymerization showed that fluvoxamine inhibits the formation of F-actin, which
induces lamellipodial protrusions, focal adhesions, and stress fibers at the edge of
GBM and is essential for the migration and invasion of GBM cells into normal brain
tissues [52–54]. The molecular signal changes in fluvoxamine-treated glioma cells are
achieved by the suppression of the activity of actin polymerization regulators, focal
adhesion kinases, and mTOR complex 2 [55, 56]. The daily administration of
fluvoxamine to an intracranial xenograft mouse model significantly prolongs survival
and blocks the infiltration of tumor cells into normal brain tissues in vivo [57].
Therefore, fluvoxamine disrupts focal adhesion and actin depolymerization, blocks
the migration and invasion ability of GBM cells, and prolongs patient survival.
Fluvoxamine is a potentially effective anti-invasive drug for the treatment of glioma.
2.5.2 Fluspirilene
Fluspirilene, a member of the diphenylbutylpiperidine class of drugs, is an
effective, traditional, long-acting antipsychotic [58, 59]. Fluspirilene displays an
effective Ca2+ channel blocking activity [60] and inhibits synaptic transmission;
thus, fluspirilene can mitigate a seizure [58]. However, recent studies have shown a
new effect of fluspirilene against some incurable cancers, such as hepatocellular
carcinoma [61] and GBM [62]. Fluspirilene has been identified as a potential anti-
GSC drug. An in vitro investigation has shown that fluspirilene not only attenuates
the cell viability, stemness, sphere-forming ability, and proliferation of GSCs but
also suppresses the invasion of GBM cells via the inhibition of signal transducer and
activator of transcription 3 (STAT3) activity and its nuclear reduction in GBM cells
[62]. In vivo, fluspirilene significantly decreases tumor volume and prolongs
8
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survival in an intracranial xenograft mouse model [62]. These results suggest that
fluspirilene is a potential novel anti-glioma candidate.
2.6 Antineoplastic drugs
2.6.1 Eribulin
Eribulin, a non-taxane inhibitor of microtubule dynamics [63, 64], was approved
by the US Food and Drug Administration (FDA) in 2010 for the treatment of stage 4
breast cancer [65]. Eribulin prevents the growth of tumor cells via the inhibition of
microtubule activity during cell mitosis and induces M-phase arrest, which result in
cell apoptosis (Figure 3) [66, 67]. Eribulin also reduces the aberrance of the vascular
microenvironment of a tumor [68]. Based on these effects on various cancers, recent
studies have demonstrated that eribulin sensitizes a tumor to radiation via eribulin-
induced M-phase arrest and causes more DNA damage than radiation alone. This
induces an increase in cleaved caspase-3 and cleaved poly-ADP ribose polymerase
levels and results in mitotic catastrophe (Figure 3) [69, 70]. An in vivo study of the
concomitant administration of radiation with eribulin showed that this combination
prolongs the survival of the intracranial xenograft GBM mouse model [71]. Eribulin
also suppresses vascular remodeling and normalizes the radiation-induced aberrant
vascular microenvironment in the xenograft mouse model [71]. A growing evidence
indicates that a telomerase reverse transcriptase (TERT) promoter mutation, a com-
mon mutation in GBM [72], maintains telomerase activity to evade telomere short-
ening; thus, tumor cells overcome replicative senescence and proliferate infinitely
[73] telomerase-independent RNA-dependent RNA polymerase (RdRP) activity
[74, 75]. Eribulin has been identified as a specific inhibitor of TERT-RdRP through
drug screening [76]. Thus, TERT-targeting therapies would be a novel direction to
treat glioma (Figure 3). Both in vitro and in vivo experiments using eribulin to treat
gliomas have shown that eribulin exerts an anticancer activity and suppresses glioma
proliferation through its function as a TERT-RdRP inhibitor, in addition to its micro-
tubule inhibitor activity. Now, eribulin is in a phase II doctor-led clinical trial in
recurrent GBM (UMIN ID: 000030359).
Figure 3.
Antitumor mechanisms of eribulin. The effect of eribulin against glioblastoma multiforme. Eribulin suppresses
microtubule activity and induces M-phase arrest, which makes cells more radiosensitive and ends up with
apoptosis. Eribulin also suppresses proliferation by inhibiting the TERT-RdRP activity.
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2.7 Anti-inflammatory drugs
2.7.1 Acetylsalicylic acid (ASA)
ASA, a nonsteroidal anti-inflammatory drug, is used worldwide. Previous stud-
ies have shown the molecular signaling changes by aspirin (Figure 4). ASA exerts
an anticancer via the inhibition of prostaglandin, including prostaglandin E2
(PGE2), synthesis through the acetylation, and inhibition of cyclooxygenase
[77, 78]. ASA treatment suppresses the invasion of glioma cells via the activation of
the expression of connexin 43 (Cx43), which is a major gap junction protein in
astrocytes. Cx43 is normally suppressed by PGE2. Thus, ASA-treated glioma cells
would overexpress Cx43 and the invasion would be inhibited [79]. Other studies
have revealed that ASA suppresses the Wnt/β-catenin/T-cell factor (TCF) signaling
pathway, which plays a key role in glioma progression [79]. Wnt/β-catenin/TCF
pathway suppression would suppress glioma via the regulation of downstream
genes, c-myc and cyclin D1. ASA inhibits the sonic hedgehog (SHH)/glioma-
associated oncogene homolog 1 (GLI1) pathway and adjusts the epithelial-to-
mesenchymal transition [80]. The SHH/GLI1 pathway is also associated with
recovery from the damage by TMZ [80]. Based on these studies, a retrospective
cohort study was performed to investigate the therapeutic effect of ASA in patients
with malignant glioma. The results revealed that the use of ASA is associated with a
higher OS and PFS in patients with WHO grade III glioma; however, there was no
difference in OS and PFS in patients with WHO grade IV glioma [81]. In the future,
prospective multicenter randomized studies are warranted to determine the effect
of ASA in malignant glioma.
2.7.2 Sulfasalazine (SAS)
SAS, which is approved for the treatment of rheumatoid arthritis and inflam-
matory bowel diseases, may be a therapeutic drug for malignant glioma [82]. SAS
exerts anti-inflammatory effects by blocking the activation of NF-κB and the Xc

antiporter system, which usually causes the uptake of cystine, release of gluta-
mate, and increase in the levels of reactive oxygen species (ROS) [83]. NF-κB is
activated in GBM tissues and promotes cell proliferation and survival. SAS blocks
Figure 4.
Antitumor mechanisms of acetylsalicylic acid. ASA indicates multimodal effects for glioma cells. ASA suppresses
the invasion of glioma cells by activating the expression of connexin 43. ASA also suppresses c-myc and cyclin
D1 through Wnt/β-catenin/TCF pathway and interfered the recovery of DNA damages and adjusted the
epithelial-to-mesenchymal transition through SHH/GLI1 pathway. Abbreviation: PGE2, prostaglandin E2.
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the cell cycle and induces apoptosis in vitro and inhibits the growth of brain
tumors in mouse xenograft models [83, 84]. However, a phase I/II study of the
current therapy with SAS for patients with recurrent malignant glioma showed no
clinical benefit of SAS [85]. Recently, a phase I/II study of the current therapy
with SAS in patients who were newly diagnosed GBM was performed [86], which
showed that there is no increase in OS and PFS in the current therapy with SAS
group compared to the current therapy group. Results suggest that this new
regimen would improve seizure control; however, the therapeutic effect of SAS
would be limited.
2.8 Multiple-drug combination therapy
A combination therapy with different drugs targeting on multiple molecules that
contribute to malignancy is rational and enhances antitumor effects, reduces side
effects, and avoids resistance. This section provides an overview of the treatment of
recurrent GBM with multiple existing drugs (Figure 5).
2.8.1 CLOVA cocktail
The CLOVA cocktail, composed of cimetidine, lithium, olanzapine, and
valproate, targets dysregulated GSK3β in GBM [87–89]. The therapeutic effects of
GSK3β inhibition are the suppression of tumor cell survival and proliferation, syn-
ergy with TMZ and irradiation, attenuation of invasion, and induction of GSC
differentiation via various pathways [90]. Olanzapine stimulates AMPK catabolic
action, followed by the induction of p53-dependent autophagy. VPA, as an HDACi,
enhances the effect of radiation. A phase I/II clinical study to investigate the effi-
cacy and safety of the CLOVA cocktail in patients with TMZ-resistant recurrent
GBM revealed that this regimen is well tolerated and results in a higher OS than the
control group treated with TMZ alone [87].
2.8.2 CUSP9* treatment
The rational of the coordinated undermining of the survival paths active in GBM
by nine repurposed drugs [aprepitant, artesunate, auranofin, captopril, celecoxib,
disulfiram (DSF), itraconazole, ritonavir, and sertraline], termed CUSP9*, was
developed to prevent therapeutic resistance in tumor cells. CUSP9* targets the
diverse complementary redundant pathways to render tumor cells susceptible to
the cytotoxic effects of TMZ [91] by the simultaneous administration of nine drugs
with low-dose daily TMZ. Each drug exerts different inhibitory effects on the 17
molecules and pathways shown in Figure 5. Auranofin and DSF increase the level of
intracellular reactive oxygen species [96]. Recently, the experimental CUSP9*
strategy with TMZ was shown to suppress the stemness of GSCs and tumorigenesis
via the blockade of the Wnt/β-catenin pathway [92].
2.8.3 FTT cocktail
A unique therapeutic approach to reprogram and reverse cancer cells to normal
somatic cells has attracted attention. The combination of fasudil, tranilast, and TMZ
was identified to reprogram GBM cells into neuronal like cells [93]. GBM cells
treated with the FTT cocktail show normal neuronal morphology, gene expression,
and electrophysiological properties and lower malignancy than untreated cells. This
might be caused by the synergistic effect of the three drugs [93]. In addition, the
FTT cocktail suppresses tumor growth and prolongs survival in a GBM xenograft
11
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Figure 5.
Multiple molecular-targeted therapies by multiple-drug treatment with temozolomide. Multiple existing drug
combination, CLOVA cocktail, CUSP9* treatment, and FTT cocktail, targets multiple signaling pathways
which attribute GBM malignant phenotype. Abbreviations: 5-LO, 5-lipoxygenase; ABCG2, ATP-binding
cassette super-family G member 2; ACE, angiotensin-converting enzyme; ALDH, aldehyde dehydrogenase;
AMPK, adenosine monophosphate; CA, carbonic anhydrase; CDK, cyclin-dependent kinase; COX,
cyclooxygenase; FAK, focal adhesion kinase; GSK3β, glycogen synthase kinase-3β; HDAC, histone
deacetylase; HH, hedgehog; JNK, c-Jun N-terminal kinase; MGMT, O6-methylguanine-DNA
methyltransferase; MMP, matrix metalloproteinase; MT, membrane type; mTOR, mammalian target of
rapamycin; NK-1, neurokinin-1; NF-κB, nuclear factor-kappaB; P-gp, P-glycoprotein; ROCK, rho-
associated protein kinase; ROS, reactive oxygen species; TCTP, translationally controlled tumor protein; TF,
tissue factor; TGF-β, transforming growth factor-β; TMZ, temozolomide; VEGF, vascular endothelial growth
factor.
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model more than TMZ alone. Fasudil inhibits the ROCK2/moesin/β-catenin path-
way in TMZ-resistant glioma cell lines and downregulates the ATP-binding cassette
super-family G member 2 transporter to increase sensitivity to TMZ [94]. The
inhibition of ROCK with mTOR inhibition exerts neuronal reprogramming more
effectively in vitro and in vivo than the inhibition of ROCK alone [95], which
suggests the possibility of more drug combinations. Tranilast alone inhibits glioma
progression via TGF-β restriction [96]. Although the mechanism underlying the
tumor-suppressive function of the FTT cocktail is not fully elucidated, this cocktail
might improve the current therapy for malignant glioma.
2.9 Other drugs
2.9.1 Disulfiram
DSF, the FDA-approved drug for the treatment of alcohol abuse, may be a
therapeutic drug for GBM. DSF is an irreversible inhibitor of aldehyde dehydroge-
nase [97], which is a functional marker of cancer stem cells [98]. An in vitro study
revealed that DSF is an inhibitor of MGMT and enhances the efficacy of alkylator-
induced tumor death [99]. Another study revealed that DSF suppresses the growth
and self-renewal of GSCs via the inhibition of polo-like kinase-1, which controls cell
progression and cytokinesis [97]. The activity of DSF is potentiated by copper and
induces GSC death [100]. However, an open-label, single-arm phase II study of
TMZ plus DSF for patients with recurrent TMZ-resistant GBM showed that the
objective response rate is 0% and DSF combination therapy would have only
limited therapeutic effects for patients with GBM [101].
2.9.2 Statins
Statins, a therapeutic drug for dyslipidemia, inhibit 3-hydroxy-3-methylglutaryl-
coenzyme A reductase. Some statins have a therapeutic effect on glioma cells
[102, 103]. In vitro, simvastatin induces the apoptosis of C6 glioma cells by phosphor-
ylation of activating transcription factor-2 and c-Jun [102]. Lovastatin suppresses the
proliferation and migration of glioma cell lines via the suppression of the activation of
ERK [103]. A retrospective cohort study suggested that the long-term prediagnostic
statin intake increases the OS in patients with GBM [104]. Another retrospective
cohort study suggested that statin intake is associated with fewer seizures in patients
with GBM [105]. However, other cohort studies have not indicated a survival rela-
tionship between malignant glioma and statin intake. Finally, a meta-analysis of these
retrospective cohort studies revealed that statins do not increase the PFS and OS in
patients with GBM [106]. In the future, prospective multicenter randomized studies
are warranted to determine the effect of statins in malignant glioma.
2.10 Pre-drugs
2.10.1 Kenpaullone
Kenpaullone, a potent and nonselective inhibitor of GSK3 [107], is a serine/
threonine kinase that regulates numerous signaling pathways involved in cell
cycle control, proliferation, differentiation, and apoptosis [108, 109].
Kenpaullone treatment inhibits glioma cell proliferation, suppresses anti-
apoptotic mechanisms in the mitochondria, inhibits pro-survival factors, and
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attenuates the stemness and viability of GSCs via the downregulated activity of
GSK3β [88, 110, 111]. The combination of low-dose kenpaullone with TMZ
enhances cytotoxicity against glioma via the induction of c-Myc-mediated apo-
ptosis [110]. These results suggest that kenpaullone is a potential compound for
the treatment of glioma.
2.10.2 2-Fluoropalmitic acid (2-FPA)
Recently, 2-FPA, a new fatty acid inhibitor compound, has been identified as a
potential anti-glioma agent through a drug screening system for drugs that target
cancer stem cells using existing drug libraries [62]. As an active chemical com-
pound, the safety of 2-FPA for normal brain cells has not yet been revealed. There
are no reports that have mentioned the effect of 2-FPA in other cancers. An in vitro
investigation using GSCs and GBM cells [112] has shown that 2-FPA suppresses the
viability and sphere-forming ability of GSCs; inhibits the proliferation of GBM cells
via the dephosphorylation of ERK, which is essential for the proliferation and
invasion of glioma [113]; and blocks the invasion of GBM cells via the suppression
of the activity of MMP-2, which plays an important role in cell invasion [114]. In
addition to its mono activity against glioma, the combination of 2-FPA with TMZ
synergistically enhances the efficacy of TMZ against glioma in vitro via the increase
in MGMT promoter methylation and downregulation of MGMT, the main and
predominant reasons for TMZ resistance [115], which suggest that combination
therapy may be one strategy to improve TMZ efficacy and overcome resistance.
Overall, 2-FPA is a potential therapeutic agent against GBM. To extend these
results, physiological studies are required.
3. Issues of drug repositioning for glioma
Despite these studies, some problems remain in drug repositioning for the treat-
ment of glioma because of the uniqueness of this brain tumor.
The biggest problem is the penetration of the blood-brain barrier (BBB), which
restricts the passage of molecules, including candidate agents. The BBB is a multi-
layered barrier between the blood and brain tissues to regulate the environment of
the brain. The BBB has a good permeability for nutrients that are required for nerve
cells [116]. Additionally, the BBB adjusts the ionic composition and the concentra-
tion of neurotransmitters, such as neuroexcitatory amino acids, to maintain the
optimal environment for synapses. If ions and neurotransmitters spread into the
CNS in an uncontrolled manner, the synapse is insufficiently stimulated and brain
tissue is damaged [116]. The BBB also prevents the penetration of macromolecules
more than 400–500 Da to exclude neurotoxic molecules [117]. Some plasma pro-
teins induce the apoptosis of nerve cells [116]. This multilayered barrier blocks
these proteins and would block the penetration of candidate agents. To overcome
this problem, techniques are being explored. Some studies have investigated a new
drug delivery system that uses an ultrasound-sensitizing nanoparticle complex, as
preliminary studies have revealed that an ultrasound with microbubbles could open
the BBB locally [118]. Other studies have evaluated the usefulness of convention-
enhanced delivery therapy, which is a local infusion therapeutic technique to
directly introduce a drug to brain neoplasms [119, 120].
A malignant glioma has features that are different from those in other malig-
nant tumors. First, a malignant glioma has heterogeneity. Some malignant cancers,
such as acute leukemia, are homogeneous; thus, the appropriate candidate agent
would induce remission because “the weak point” of all tumor cells is the same.
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However, a malignant glioma is a complicated aggregation, once called “glioblas-
toma multiforme” [121]. If one candidate agent exerts therapeutic effects for some
glioma cells, other resistant glioma cells would multiply. To overcome this prob-
lem, several previous studies have performed multiple-drug combination therapy.
This therapy would focus on multiple therapeutic targets at once with minimal side
effects [85]; however, currently, there are no combination treatments that can
replace the current treatments. Second, despite its clinical aggressiveness, 60–70%
of the tumor cells in malignant glioma are in the nonproliferating phase [122]. This
indicates that not only heterogeneous cells but also the cell cycle must be consid-
ered because resting cells indicate resistance to chemoradiotherapy [122]. Based on
this, some studies have focused on candidate agents that can change the phase of
the cell cycle [18, 45].
4. Perspective
The strategy to discover the most effective drug is the key to accomplish a
successful drug repositioning. One of the main methods is an in vitro or in vivo drug
screening system in which target cells are treated by various existing drugs and the
alteration to the malignant phenotype, such as by cytotoxicity, is analyzed. Drugs
that exert cytotoxicity in GBM cells, especially GSCs, at low concentrations would
be good candidates. Since the previous reports mention that GSCs were the cause of
recurrence of GBM [100], GSCs can be good target. Lower drug concentration can
minimize side effects. However, to achieve this strategy, appropriate experimental
resources, including candidate agents, drug screening systems, and established cell
lines are required. Epidemiological discovery is another option, such as the mea-
surement of the incidence of a certain disease in the population to which specific
drugs are administered. Serendipity is an important factor in this strategy. For
instance, a prospective cohort study revealed a lower cancer incidence in people
with schizophrenia [123]. This led us to the idea that antipsychotic drugs possess
therapeutic effects against cancers including glioma [57, 62]. However, the most
efficient method might be mutual molecular and structure analyses between target
cells and drugs using artificial intelligence (AI). Different biochemical and mathe-
matical techniques have been designed and optimized to accurately infer links
between target cells and drugs. Drug-target interaction prediction is an important
part of most rational drug repositioning pipelines. The major target molecules for
malignant glioma are Akt, ERK, and STAT3, which sustain malignant phenotype
[62, 103, 113].
The supply of research resources is also important. Pharmaceutical companies
hold the materials for drug repositioning such as drug libraries and useful knowl-
edge for bringing new drugs to market. Thus, a collaboration between researchers
who establish efficient screening systems and pharmaceutical companies that own
various drugs, including those that failed in clinical trials, can lead to a successful
drug repositioning.
Although drug repositioning may be useful in the future, there are hurdles to the
transition of this research into clinical practice owing to financial problems. Drug
repositioning involves reinvestment in inexpensive drugs with expired patents;
therefore, the benefits to pharmaceutical companies are small, which results in a
reluctance to cooperate to broaden the indications of their drugs. This is especially
true for rare diseases, such as glioma. Currently, the only way for researchers to
raise public and private funds is by themselves, and they must conduct physician-
led clinical trials without the support of pharmaceutical companies. An effective
system in which the government supports drug repositioning is required to
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overcome the issue of budget constraints. From an economic perspective, it would
be beneficial to patients and countries to treat patients with inexpensive drugs with
expired patents.
After the appearance of TMZ, drug development for GBM has stagnated. A huge
advance in the treatment of patients with GBM can be expected if effective drugs
are identified via drug repurposing.
5. Conclusion
Drug repositioning is a useful research strategy to identify the therapeutic agents
for glioma. Here, we discuss the current drug repositioning and its perspective for
glioma treatment. Despite many efforts to date, no agents are widely used in the
current clinical practice. For breaking down the current situation, appropriate
screening system, suitable animal model, well-designed clinical trials, and tight
collaboration with pharmaceutical companies are warranted. From now on, the
drastic progress in this field would be occurred by new methods including AI.
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